Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;10(7):389.
doi: 10.21037/atm-21-6999.

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer

Roberta Maltoni  1 , Sara Bravaccini  1
Affiliations
Editorial

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer

Roberta Maltoni et al. Ann Transl Med. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-21-6999/coif). The authors have no conflicts of interest to declare.

Comment on

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.

References

    1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021;384:1529-41. 10.1056/NEJMoa2028485 - DOI - PubMed
    1. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan vs. chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 2021;32:1148-56. 10.1016/j.annonc.2021.06.002 - DOI - PubMed
    1. Bravaccini S, Maltoni R. Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls. J Pers Med 2021;11:1211. 10.3390/jpm11111211 - DOI - PMC - PubMed
    1. Time to care report. Available online: https://www.intexo.it/wp-content/uploads/2021/05/02_Febbraio_2021_time_t... (accessed on 12 November 2021).
    1. Schreiber AR, Andress M, Diamond JR. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther 2021;21:1303-11. 10.1080/14737140.2021.1993065 - DOI - PubMed